Predicting long-term kidney graft survival: can new trials be performed?1,2
暂无分享,去创建一个
D. Dunn | A. Matas | J. Najarian | R. Kandaswamy | D. Sutherland | S. Paraskevas | R. Gruessner | A. Humar | W. Payne | K. Gillingham
[1] D. Dunn,et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. , 2002, Kidney international.
[2] Christopher P. Johnson,et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. , 2002, Kidney international.
[3] B. Kasiske,et al. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] J. Fink,et al. Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] B. Kasiske,et al. Comparing methods for monitoring serum creatinine to predict late renal allograft failure. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] T. Shimizu,et al. Time-dependent risk factors influencing the long-term outcome in living renal allografts: donor age is a crucial risk factor for long-term graft survival more than 5 years after transplantation. , 2001, Transplantation.
[7] D. Dunn,et al. 2,500 Living Donor Kidney Transplants: A Single-Center Experience , 2001, Annals of surgery.
[8] S. Birkeland. STEROID-FREE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A LONG-TERM FOLLOW-UP OF 100 CONSECUTIVE PATIENTS , 2001, Transplantation.
[9] Barry D Kahan,et al. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.
[10] S. Hariharan,et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.
[11] G. Jhangri,et al. Time dependency of factors affecting renal allograft survival. , 2000, Journal of the American Society of Nephrology : JASN.
[12] A. Matas,et al. Immunologic factors: the major risk for decreased long-term renal allograft survival. , 1999, Transplantation.
[13] S. Kim,et al. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. , 1999, Transplantation.
[14] S. Birkeland. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. , 1998, Transplantation.
[15] F. Cosio,et al. Factors related to the donor organ are major determinants of renal allograft function and survival. , 1996, Transplantation.
[16] Sollinger Hw. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .
[17] B. Kasiske,et al. CLINICAL IMPACT OF REPLACING MINNESOTA ANTILYMPHOCYTE GLOBULIN WITH ATGAM , 1995, Transplantation.
[18] W. Payne,et al. THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 , 1994, Transplantation.
[19] G. Abouna,et al. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. , 1993, Transplantation Proceedings.
[20] D. Dunn,et al. Early versus late acute renal allograft rejection: impact on chronic rejection. , 1993 .
[21] D. Dunn,et al. Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.
[22] D. Dunn,et al. RENAL TRANSPLANT FUNCTION AFTER TEN YEARS OF CYCLOSPORINE , 1992, Transplantation.
[23] D. Dunn,et al. Causes of Renal Allograft Loss: Progress in the 1980s, Challenges for the 1990s , 1991, Annals of surgery.
[24] T. Hostetter,et al. Progression of kidney disease in chronic renal transplant rejection. , 1991, Transplantation.
[25] B. Kasiske,et al. The variable nature of chronic declines in renal allograft function. , 1991, Transplantation.
[26] D. Sutherland,et al. A Single Institution, Randomized, Prospective Trial of Cyclosporine Versus Azathioprine‐Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients , 1985, Annals of surgery.
[27] G. Klintmalm,et al. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. , 1985, Transplantation.
[28] A. Melk,et al. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. , 1999, Journal of the American Society of Nephrology : JASN.
[29] H. Sollinger. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995, Transplantation.
[30] D. Dunn,et al. Effect of cyclosporine on renal function in kidney transplant recipients: a 12-year follow-up. , 1995, Clinical transplantation.